The potential of generative AI in Europe’s pharmaceutical landscape

What if, during the COVID-19 crisis, generative artificial intelligence (AI) had already been part of our scientific toolbox? It could have screened billions of molecules in days, simulated clinical outcomes with synthetic data, and helped regulators review safety documentation faster. The pandemic might not have been less severe, but our response could have been far more agile, data-driven, and globally coordinated. The lesson is clear: AI is no longer optional; it is essential to Europe’s resilience, competitiveness, and public health preparedness.

Europe’s vision: becoming the AI Continent

The European Union has set a clear ambition: to make Europe the AI Continent. Through strategic frameworks such as the Digital Decade Policy and its roadmap, the Digital Compass, together with the AI Action Plan and the GenAI4EU initiative and the recently published policy Apply AI Strategy, Europe is investing in trustworthy, human-centric AI as a driver of competitiveness, innovation, and strategic autonomy.

The Digital Decade Policy defines the 2030 vision: ensuring that Europe not only adopts AI technologies but also develops its own models, infrastructure, and governance frameworks grounded in European values, such as ethics, transparency, and human-centred innovation.

Within this framework, the AI Action Plan coordinates research, investment, and regulation across Member States, creating the right conditions for responsible and sustainable growth. Programmes such as GenAI4EU and InvestAI are already mobilising hundreds of millions of euros to strengthen Europe’s AI ecosystem – supporting trustworthy generative models, expanding computing capacity, and connecting startups, researchers, and industry.

This strategic momentum reflects a geopolitical truth: AI has become a matter of sovereignty. If Europe wants to safeguard its economic and scientific independence, it must lead not only in using AI but also in how AI is designed, deployed, and governed, ensuring that technological progress aligns with its social values and industrial strengths.

Among the sectors that best embody this ambition, pharmaceuticals and life sciences stand out. Europe’s excellence in research and regulation can merge with AI’s transformative power — paving the way for faster drug discovery, smarter clinical trials, and a new era of personalised medicine.

Pharma’s challenge and the promise of generative AI

The pharmaceutical sector is one of Europe’s most advanced and research-intensive industries, driving global progress in science and healthcare. Yet its innovation processes remain long, costly, and highly regulated by necessity. Every new treatment must pass rigorous scientific and ethical validation before reaching patients. Data is often fragmented across hospitals, laboratories, and national systems, while compliance frameworks add further layers of complexity.

In this context, generative AI offers an opportunity to accelerate innovation without compromising safety or integrity. Unlike traditional AI, which analyses existing data, generative AI can create new information – from text and images to molecular structures and synthetic biomedical data – enabling faster exploration, simulation, and decision-making across the R&D chain.

Its potential spans the full life cycle of medicine development:

• Drug discovery: generating and testing molecular designs digitally before physical synthesis.
• Clinical trials: identifying patient cohorts and predicting outcomes faster and more precisely.
• Synthetic data generation: enabling research when access to real data is limited by privacy or scarcity.
• Regulatory and documentation support: drafting technical files, summarising evidence, and automating compliance.
• Personalised medicine: combining genomic and clinical data to design tailored therapies.

The European Medicines Agency (EMA) recognises this potential through its Artificial Intelligence Workplan 2023–2028, which sets the path for safe, ethical, and transparent AI use in medicine regulation.

What still holds Europe back

Despite this promise, Europe must overcome several structural barriers to fully realise AI’s potential in the pharmaceutical sector.

First, data fragmentation and limited access to high-performance computing slow collaboration and innovation. Talent shortages in the intersection of AI, life sciences, and ethics further constrain progress.

Second, the regulatory environment, led by the EU AI Act, while crucial for trust, imposes complex obligations for high-risk applications. Compliance with overlapping frameworks — GDPR, Medical Devices Regulation (MDR), and Good Manufacturing Practice (GMP) — often burdens smaller firms.

Finally, organisational resistance, high costs, and dependency on global technology platforms continue to hinder adoption, weakening Europe’s digital autonomy.

To move forward, Europe must coordinate investments in interoperable health data spaces, shared computing infrastructure, AI regulatory sandboxes, and cross-disciplinary training that bridges data science and medicine.

The AI Continent takes shape

Europe’s journey to become the AI Continent is gaining momentum. With the Digital Decade Policy, AI Action Plan, GenAI4EU, and the AI Act, the EU is building a distinctive model of technological leadership, innovation with trust.

In the pharmaceutical field, Generative AI is not just a tool; it is a strategic catalyst that could redefine how we prepare for global health challenges, from future pandemics to chronic disease management. The COVID-19 experience already proved how fast humanity can act when science and collaboration align. With AI now part of Europe’s DNA, the next challenge is clear: to move from ambition to leadership and truly build the AI Continent.